Steminent Biotherapeutics (ROCO:7729) ROE % Adjusted to Book Value: -6.36% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7729 Steminent Biotherapeutics Inc ROCO:7729
11 GF Score
Price NT$73.00
! 4 Warning Signs
View Full Analysis

What is Steminent Biotherapeutics ROE % Adjusted to Book Value?

Steminent Biotherapeutics ROCO:7729 -4.70% 11 ROE % Adjusted to Book Value is -6.36% as of Dec. 2025. GuruFocus rates ROCO:7729 with a GF Score™ of 11/100. The stock has 4 warning signs investors should review.

Steminent Biotherapeutics's ROE % for the quarter that ended in Dec. 2025 was -42.42%. Steminent Biotherapeutics's PB Ratio for the quarter that ended in Dec. 2025 was 6.67. Steminent Biotherapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -6.36%.

Steminent Biotherapeutics ROE % Adjusted to Book Value Related Terms

Steminent Biotherapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Steminent Biotherapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Steminent Biotherapeutics ROE % Adjusted to Book Value Chart

Steminent Biotherapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial 0.00 0.00 0.00 -10.32 -5.46

Steminent Biotherapeutics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -9.82 -10.66 -12.22 -6.36

ROCO:7729 vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Steminent Biotherapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Steminent Biotherapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Steminent Biotherapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Steminent Biotherapeutics's ROE % Adjusted to Book Value falls into.


ROCO:7729
11GF Score
Steminent Biotherapeutics Inc ROCO:7729
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Steminent Biotherapeutics ROE % Adjusted to Book Value Calculation

Steminent Biotherapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-36.42% / 6.67
=-5.46%

Steminent Biotherapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-42.42% / 6.67
=-6.36%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -6.36% mean?
Steminent Biotherapeutics (ROCO:7729) has a ROE % Adjusted to Book Value of -6.36% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Steminent Biotherapeutics and its competitors.
Is Steminent Biotherapeutics' ROE % Adjusted to Book Value too high?
Steminent Biotherapeutics' current ROE % Adjusted to Book Value is -6.36%. Overall, Steminent Biotherapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Steminent Biotherapeutics' ROE % Adjusted to Book Value compare to VRTX and REGN?
Steminent Biotherapeutics' ROE % Adjusted to Book Value of -6.36% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Steminent Biotherapeutics and its competitors. Steminent Biotherapeutics's current ROE % Adjusted to Book Value is -6.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Steminent Biotherapeutics stock overvalued right now?
Steminent Biotherapeutics (ROCO:7729) has a current ROE % Adjusted to Book Value of -6.36%. The current ROE % Adjusted to Book Value is -6.36%. Steminent Biotherapeutics' overall GF Score™ is 11/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Steminent Biotherapeutics (ROCO:7729), the current ROE % Adjusted to Book Value is -6.36% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Steminent Biotherapeutics Business Description

Address No.16,Wenhu Street, Neihu District, Taipei, TWN, 11445
Steminent Biotherapeutics Inc is a international stem cell biopharmaceutical company which has stable and efficient stem cell platform technology, aiming to develop live cell drugs to treat degenerative diseases as well as acute and life-threatening diseases. With its Stemchymal which is proprietary technology platform generating the standardized, clinical grade, allogeneic stem cells isolated from human adipose tissue. It is operated in strict compliance to regulations of Taiwan, the US, and Japan.
11GF Score

Get the complete analysis for ROCO:7729

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$73.00
Price